Boenning & Scattergood Starts Elite Pharmaceuticals (ELI) at Market Outperform
More News related to ELI
- Oppenheimer Starts Elite Pharma (ELI) at Buy
- Boenning & Scattergood Starts Elite Pharmaceuticals (ELI) at Market Outperform
- Elite Pharmaceuticals (ELI) Provides Positive Clinical Update
- Elite Pharmaceutical (ELI) and ECR Launch Second Once-Daily Antihistamine
- Elite Pharmaceuticals (ELI) Announces Strategic Alliance with Dr. Veerappan Subramanian
More News related to New Coverage
- Wright Medical Group (WMGI) Announces FDA Approval For CONSERVE Plus Total Hip Resurfacing System
- Vascular Solutions (VASC) Receives 501(k) Clearance from U.S. FDA for GuideLiner Catheter
- Glaxo (GSK) and XenoPort (XNPT) Announed that U.S. FDA Has Extended the Review Date of GSK1838262/XP13512
- Compugen (CGEN) Announces Discovery of Biomarker CGEN-40001 for Type 2 Diabetes
Boenning & Scattergood initiates coverage on Elite Pharmaceuticals Inc. (AMEX: ELI) with a Market Outperform rating and $4 price target.
Analyst Debjit Chattopadhyay, Ph.D said, "We believe Elite is poised to advance two pain products into Phase III trials later this year, which we think could lead to significant commercialization deals."
Related Categories
New CoverageStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
